Non Small Cell Lung Cancer Clinical Trial
— ROSIEOfficial title:
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Verified date | March 2024 |
Source | Intergroupe Francophone de Cancerologie Thoracique |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
IFCT-2202 ROSIE study aims to incorporate a broad-panel centralized NGS testing at baseline in all patients with completely resected NSCLC with common EGFR mutation after confirmation of an optimal preoperative extension assessment and with a centralized review of the quality of the surgical excision. Furthermore, the IFCT-2202 ROSIE study also aims to study the molecular events associated with relapse on, or after osimertinib exposure, that should result in the opportunity to accede to optimal treatment in case of metastatic relapse.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | October 2031 |
Est. primary completion date | October 2031 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed Informed consent. 2. Age = 18 years. 3. Pre-surgical disease evaluation including brain MRI/CT-scan and total body PET-FDG CT-scan prior to surgery. 4. Histologically complete anatomical resection (R0) of stage pIB-IIIA (pTNM 8th edition) NSCLC. 5. Presence of a common EGFR mutation (Del19 or L858R). 6. Archival tumour tissue FFPE blocks from surgery available for centrally molecular analyses. 7. Patient eligible to receive osimertinib adjuvant therapy in a 3-year intent to treat decision; patients could receive if necessary adjuvant chemotherapy before starting osimertinib treatment. 8. Patient who is capable, according to the investigator, of complying with the study's requirements and restrictions. 9. Patient followed in the institution on a regular basis (every 3 to 6 months) according to standard recommendations. 10. Estimated life expectancy > 3 years. 11. Woman patients who are of childbearing potential are eligible: - They must have a negative pregnancy test before the first dose of osimertinib. - They must agree to use effective methods of contraception throughout the course of treatment and should be maintained for 2 months after the end of treatment. 12. Male subjects who are sexually active with a woman of childbearing potential are eligible if an efficacious contraception method should be used during the treatment and during the 4 months following the last dose. Exclusion Criteria: 1. History of cancer, except for the following situations: Patients with history of cancer for more than 3 years are eligible if they have been treated and considered cured. Patients with history of in situ carcinoma of the cervix or non-melanoma skin carcinoma are eligible. 2. Neoadjuvant anti-cancer treatment (osimertinib and/or chemotherapy or other anti-cancer treatment). 3. Incompletely resected NSCLC (R1 or R2). 4. Any medical condition that would, according to the investigator's judgment, prevent the patient's participation in the clinical study. 5. Active infection (e.g. patients receiving treatment for infection) including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), or active uncontrolled hepatitis B infection except for the situations described in APPENDIX I. Screening for chronic conditions is not required. |
Country | Name | City | State |
---|---|---|---|
France | Angers - CHU | Angers | |
France | Bayonne - CH | Bayonne | |
France | Boulogne - Ambroise Paré | Boulogne | |
France | Lyon - URCOT | Bron | |
France | Caen - CHU | Caen | |
France | Clermont-Ferrand - CHU | Clermont-Ferrand | |
France | Colmar - CH | Colmar | |
France | Créteil - CHI | Créteil | |
France | Dijon - CHU Bocage | Dijon | |
France | Grenoble - CHU | Grenoble | |
France | La Roche-Sur-Yon - CH | La Roche-sur-Yon | |
France | Le Mans - CHG | Le Mans | |
France | Lille - CHU | Lille | |
France | Lyon - CRLCC | Lyon | |
France | Marseille - APHM | Marseille | |
France | Metz - Hôpital Robert Schuman | Metz | |
France | Montpellier - CHU | Montpellier | |
France | Montpellier - ICM | Montpellier | |
France | Nice - CHU | Nice | |
France | Orléans - CHR | Orléans | |
France | Paris - Bichat | Paris | |
France | Paris - HEGP | Paris | |
France | Paris - Hôpital Cochin | Paris | |
France | Paris - Pitié-Salpêtrière | Paris | |
France | Paris - Tenon | Paris | |
France | Pau - CHG | Pau | |
France | Bordeaux - CHU | Pessac | |
France | Poitiers - CHU | Poitiers | |
France | Annecy - CH | Pringy | |
France | Rennes - CHU | Rennes | |
France | Rouen - CHU | Rouen | |
France | Strasbourg - NHC | Strasbourg | |
France | Suresnes - Foch | Suresnes | |
France | Toulon - CHI | Toulon | |
France | Toulouse - CHU | Toulouse | |
France | Tours - CHU | Tours |
Lead Sponsor | Collaborator |
---|---|
Intergroupe Francophone de Cancerologie Thoracique |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility study | Number of patients included receiving osimertinib after 18 months of enrollment | 18 months | |
Secondary | Incidence, nature, and severity of osimertinib-related adverse events (safety) | Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0). | About 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |